Perspective Therapeutics, Inc. (NYSE:CATX) Holdings Lifted by WealthPlan Investment Management LLC

WealthPlan Investment Management LLC raised its holdings in shares of Perspective Therapeutics, Inc. (NYSE:CATX) by 18.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 401,049 shares of the company’s stock after acquiring an additional 61,757 shares during the quarter. WealthPlan Investment Management LLC’s holdings in Perspective Therapeutics were worth $1,279,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in CATX. Vontobel Holding Ltd. purchased a new stake in Perspective Therapeutics in the 4th quarter worth approximately $51,000. nVerses Capital LLC purchased a new stake in shares of Perspective Therapeutics during the third quarter worth $57,000. Trueblood Wealth Management LLC increased its position in Perspective Therapeutics by 37.0% in the 4th quarter. Trueblood Wealth Management LLC now owns 22,236 shares of the company’s stock worth $71,000 after purchasing an additional 6,000 shares during the last quarter. Koa Wealth Management LLC purchased a new stake in shares of Perspective Therapeutics during the 4th quarter worth about $83,000. Finally, SG Americas Securities LLC increased its holdings in Perspective Therapeutics by 41.3% in the fourth quarter. SG Americas Securities LLC now owns 26,088 shares of the company’s stock worth $83,000 after buying an additional 7,627 shares during the last quarter. Institutional investors and hedge funds own 54.66% of the company’s stock.

Perspective Therapeutics Stock Performance

Perspective Therapeutics stock opened at $3.02 on Friday. Perspective Therapeutics, Inc. has a one year low of $2.70 and a one year high of $19.05. The business has a 50 day simple moving average of $3.39 and a 200 day simple moving average of $8.87.

Perspective Therapeutics (NYSE:CATX) last announced its earnings results on Tuesday, November 12th. The company reported ($0.21) EPS for the quarter, hitting the consensus estimate of ($0.21). The business had revenue of $0.37 million for the quarter. Perspective Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,096.66%. As a group, sell-side analysts anticipate that Perspective Therapeutics, Inc. will post -0.88 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have weighed in on CATX. Oppenheimer cut their target price on Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating on the stock in a report on Friday, November 22nd. Royal Bank of Canada reaffirmed an “outperform” rating and set a $16.00 price objective on shares of Perspective Therapeutics in a report on Tuesday, January 14th. Cantor Fitzgerald upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a report on Wednesday, February 5th. UBS Group started coverage on Perspective Therapeutics in a research note on Thursday, October 24th. They issued a “buy” rating and a $20.00 price objective on the stock. Finally, Bank of America lowered Perspective Therapeutics from a “buy” rating to a “neutral” rating and lowered their target price for the company from $24.00 to $5.00 in a report on Monday, November 25th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $15.14.

Insider Buying and Selling at Perspective Therapeutics

In other news, CEO Johan M. Spoor purchased 14,500 shares of Perspective Therapeutics stock in a transaction dated Monday, November 25th. The shares were bought at an average cost of $3.78 per share, with a total value of $54,810.00. Following the completion of the transaction, the chief executive officer now directly owns 152,072 shares in the company, valued at $574,832.16. This trade represents a 10.54 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Jonathan Robert Hunt purchased 12,829 shares of the stock in a transaction on Monday, November 25th. The stock was acquired at an average price of $3.82 per share, with a total value of $49,006.78. Following the completion of the acquisition, the chief financial officer now directly owns 48,800 shares of the company’s stock, valued at approximately $186,416. This represents a 35.66 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders acquired 67,570 shares of company stock worth $256,789. Insiders own 3.52% of the company’s stock.

Perspective Therapeutics Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.